Bristol-Myers Squibb (BMY) is experiencing a significant uptick, with shares surging by 15% following multiple drug approvals, offering potential for a bargain by 2025. Key competitor, Bayer's positive update brings more optimism to BMY investors. Shares of BMY are further bolstered by acquisitions from Norges Bank and Skandinaviska Enskilda Banken AB publ. Despite trial failures, such as the joint venture between BMY and J&J for a next-generation blood thinner, BMY was able to rebound their share price. While brokerage committees rate BMY a hold, Jim Cramer expressed disappointment with BMY’s Cobenfy, which is presently underperforming in sales. BMY's successes include gaining EU approval for their Mantle Cell Lymphoma treatment, Breyanzi, and strong revenue from Opdivo sales outpacing projections. Despite some setbacks, BMY's commitment to R&D, ability to bounce back, and several acquisitions suggest potential for growth. A strategic partnership with Evotec and the $1.5 billion Orbital acquisition suggest a focused approach to innovation. Observers still see value in BMY, despite some setbacks, aided by an improved revenue outlook.
Bristol-Myers Squibb News Analytics from Tue, 06 May 2025 07:00:00 GMT to Sat, 29 Nov 2025 14:38:43 GMT -
Rating 2
- Innovation 6
- Information 8
- Rumor -3
